The lancet. Diabetes & endocrinology

The most recent articles from: Lancet Diabetes Endocrinol December 2015

Lancet Diabetes Endocrinol · Dec 2015

Randomized Controlled Trial Multicenter Study

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.

Myostatin inhibits skeletal muscle growth. The humanised monoclonal antibody LY2495655 (LY) binds and neutralises myostatin. We aimed to test whether LY increases appendicular lean body mass (aLBM) and improves physical performance in older individuals who have had recent falls and low muscle strength and power. ⋯ Eli Lilly and Company.

expand abstract… or not…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,706,642 articles already indexed!